MCID: NRN004
MIFTS: 58

Neuroendocrine Tumor

Categories: Rare diseases, Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neuroendocrine Tumor

MalaCards integrated aliases for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 76 53 15
Neuroendocrine Neoplasm 12 53 29 6
Neuroendocrine Tumors 55 44 73
Carcinoma, Neuroendocrine 44 73
Neuroendocrine Carcinoma 12 15
Neuroendocrine Neoplasia 53
Carcinoma Neuroendocrine 55
Neuroendocrine Cancer 76

Classifications:



External Ids:

Disease Ontology 12 DOID:169 DOID:1800
ICD10 33 D3A.8
ICD9CM 35 209 209-209.99
NCIt 50 C3809 C3773

Summaries for Neuroendocrine Tumor

NIH Rare Diseases : 53 A neuroendocrine tumor (NET) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells. These cells have traits of both nerve cells and hormone-producing cells, and release hormones into the blood in response to signals from the nervous system. Because a neuroendocrine tumor arises from cells that produce hormones, the tumor can also produce hormones. Neuroendocrine tumors can develop anywhere in the body, but most occur in the digestive tract, pancreas, rectum, lungs, or appendix. They can be non-cancerous (benign) or cancerous (malignant). They usually grow slowly over many years, but there are fast-growing forms. There are many types of neuroendocrine tumors, but most are classified as one of two main types:Carcinoid tumors - NETs that most commonly arise in the digestive tract, lungs, appendix or thymus. They can also grow in the lymph nodes, brain, bone, gonads (ovaries and testes) or skin. Pancreatic neuroendocrine tumors (also called islet cell tumors) - NETs that typically arise in the pancreas, although they can occur outside the pancreas. A pheochromocytoma is another, rarer type of NET that usually develops in the adrenal gland, but can also arise in other parts of the body. Signs and symptoms depend on the tumor's type, size and location; whether it produces hormones; and whether it has spread to other parts of the body (metastasized). NETs are typically described as functional or nonfunctional. Functional NETs produce a specific set of symptoms due to the production of excess hormones, while non-functional NETs generally do not cause specific symptoms. In many cases, a person has no symptoms until the tumor spreads to the liver and/or impairs the function of an organ or system. This can make NETs very hard to diagnose. The majority of NETs are not inherited and occur sporadically in people with no family history of NETs. However, some NETs are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (most commonly), Von Hippel-Lindau disease, tuberous sclerosis, or neurofibromatosis type 1 (NF1). Inheritance of each of these is autosomal dominant. Treatment of NETs depends on many factors such as the tumor's type, location, aggressiveness, and hormone-producing capabilities; as well as whether it has metastasized. Management options may include surveillance, surgery to remove the tumor and/or surrounding tissue, and various non-surgical therapies to shrink the tumor, stop it from growing, or manage symptoms.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine neoplasm, is related to gastrointestinal neuroendocrine tumor and esophageal neuroendocrine tumor. An important gene associated with Neuroendocrine Tumor is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Afinitor and Sutent have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and brain, and related phenotypes are endocrine/exocrine gland and digestive/alimentary

Disease Ontology : 12 An endocrine gland cancer that has material basis in neuroendocrine cells.

Wikipedia : 76 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 421)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal neuroendocrine tumor 34.5 CHGA SST SYP
2 esophageal neuroendocrine tumor 34.1 CHGA NCAM1 SYP
3 insulinoma 33.2 CHGA INSM1 MEN1 SST
4 gastric neuroendocrine neoplasm 33.1 CHGA GAST SST
5 gastrinoma 32.9 CHGA GAST MEN1 SST
6 gastric gastrinoma 32.8 ENO2 GAST
7 ovary neuroendocrine neoplasm 32.7 KRT7 SYP
8 duodenal somatostatinoma 32.4 CALCA ENO2 SST
9 phaeochromocytoma 32.2 CHGA SDHD SST
10 von hippel-lindau syndrome 32.2 CHGA CHGB MEN1 SDHD
11 duodenal gastrinoma 31.8 CHGA ENO2 GAST GRP MEN1 SST
12 goblet cell carcinoid 31.7 CHGA ENO2 GAST KRT20
13 multiple endocrine neoplasia 31.7 CALCA CHGA MEN1
14 acromegaly 31.0 MEN1 SST SSTR2
15 pancreatic cancer 30.9 GAST GRP KRT19 MEN1 NTS SST
16 atrophic gastritis 30.8 CHGA GAST SST
17 glucagonoma 30.7 CHGA CHGB SST
18 ectopic cushing syndrome 30.4 MEN1 SST SYP
19 pulmonary large cell neuroendocrine carcinoma 30.4 CHGA ENO2 SYP
20 duodenal ulcer 30.4 GAST GRP SST
21 ependymoma 30.2 ENO2 MEN1 SYP
22 cowden disease 30.2 CALCA CHGA SDHD
23 multiple endocrine neoplasia, type i 30.2 CHGA GAST MEN1 SDHD SST SYP
24 somatostatinoma 30.1 CALCA CHGA ENO2 SST
25 vipoma 30.1 CHGA GAST NTS SST
26 paraganglioma 30.0 CHGA ENO2 SDHD SST SYP
27 gastrointestinal stromal tumor 29.7 CHGA ENO2 MEN1 SDHD SYP
28 carcinoid syndrome 29.6 CALCA CHGA ENO2 MEN1 NTS SST
29 thyroid cancer 29.2 CALCA CHGA KRT19 NKX2-1 SST
30 pheochromocytoma 29.1 ASCL1 CALCA CHGA CHGB ENO2 MEN1
31 thymus cancer 29.1 KRT7 NKX2-1 SYP
32 teratoma 29.1 ENO2 KRT7 NKX2-1 SYP
33 cystadenoma 28.8 CHGA KRT20 KRT7 SYP
34 polycystic liver disease 1 with or without kidney cysts 28.6 KRT19 KRT20 KRT7
35 sclerosing hemangioma 28.4 CHGA ENO2 KRT7 NKX2-1 SYP
36 renal cell carcinoma, nonpapillary 27.8 KRT19 KRT20 KRT7 NKX2-1
37 cystic teratoma 27.5 ENO2 KRT20 KRT7 NKX2-1 SYP
38 horseshoe kidney 27.3 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
39 thyroid carcinoma, familial medullary 27.2 CALCA CHGA CHGB ENO2 GAST GRP
40 lung cancer 26.2 ASCL1 CHGA ENO2 GRP KRT19 KRT7
41 merkel cell carcinoma 25.9 CHGA ENO2 KRT20 KRT7 NCAM1 NKX2-1
42 large cell neuroendocrine carcinoma 25.8 ASCL1 CHGA ENO2 KRT20 KRT7 NCAM1
43 small cell carcinoma 25.4 ASCL1 CALCA CHGA ENO2 KRT20 KRT7
44 small cell cancer of the lung 23.3 ASCL1 CALCA CHGA ENO2 GAST GRP
45 pancreatic neuroendocrine tumor 12.4
46 pulmonary neuroendocrine tumor 12.3
47 neuroendocrine carcinoma of the cervix 12.2
48 laryngeal neuroendocrine tumor 12.1
49 anal neuroendocrine tumor 12.1
50 non-functioning neuroendocrine tumor of pancreas 12.1

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 INSM1 KRT19 MEN1 NKX2-1 ASCL1 SDHD
2 digestive/alimentary MP:0005381 9.8 GAST INSM1 KRT19 MEN1 NKX2-1 SST
3 nervous system MP:0003631 9.8 GRP INSM1 KRT19 MEN1 NCAM1 NKX2-1
4 no phenotypic analysis MP:0003012 9.23 INSM1 KRT19 NKX2-1 NTS ASCL1 CHGA

Drugs & Therapeutics for Neuroendocrine Tumor

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 646)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
4
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
5
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 38916-34-6, 51110-01-1 53481605
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
10
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
12
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 83150-76-9 383414 6400441
13
Pancrelipase Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 53608-75-6
14
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
15
Trametinib Approved Phase 4,Phase 3,Phase 1,Phase 2 871700-17-3 11707110
16
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
17
nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 946414-94-4
18
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
19
Palbociclib Approved, Investigational Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
20
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
21
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
22 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
25
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
26
Aminolevulinic acid Approved Phase 4 106-60-5 137
27
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
28
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
29
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
30
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
31
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
32
Ceritinib Approved Phase 4,Phase 2 1032900-25-6
33
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34
Olaparib Approved Phase 4 763113-22-0 23725625
35
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
36
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
37 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
50 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2541)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
4 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
5 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
6 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4 RAD001
7 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
8 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
9 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
10 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
11 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
12 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
13 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
14 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
15 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
16 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
17 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
18 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
19 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
20 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
21 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
22 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
23 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
24 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
25 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
26 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
27 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
28 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
29 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
30 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
31 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
32 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
33 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
34 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
35 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
36 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
37 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
38 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
39 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
40 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
41 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
42 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Unknown status NCT01280565 Phase 3 masitinib;Dacarbazine
43 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
44 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
45 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
46 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
47 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
48 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
49 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
50 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3

Search NIH Clinical Center for Neuroendocrine Tumor

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

# Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 29

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

41
Lung, Liver, Brain, Thyroid, Skin, Lymph Node, Kidney

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 1361)
# Title Authors Year
1
A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation. ( 29432346 )
2018
2
Demonstration of Treatment Response to Trans-arterial Radio-embolization (TARE) on 68Ga-DOTANOC PET/CT in a Patient With Metastatic Neuroendocrine Tumor. ( 29939955 )
2018
3
Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. ( 29503572 )
2018
4
Reply to: Genotype-Phenotype Pancreatic Neuroendocrine Tumor Relationship in Multiple Endocrine Neoplasia Type 1 Patients: A 23 Year Experience at a Single Institution. ( 29859614 )
2018
5
Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. ( 29698969 )
2018
6
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. ( 29330294 )
2018
7
Hepatobiliary and Pancreatic: Malignant pancreatic perivascular epithelioid cell tumor mimicking pancreatic neuroendocrine tumor. ( 29888489 )
2018
8
Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. ( 29594467 )
2018
9
Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. ( 29122330 )
2018
10
Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: The value of WHO 2010 classification. ( 29536058 )
2018
11
Hypoglycemia in a Patient With a Polyhormonal Pancreatic Neuroendocrine Tumor With Evidence of Endocrine Progenitors. ( 29568813 )
2018
12
Neuroendocrine tumor of the pancreas with rhabdoid feature. ( 29938394 )
2018
13
Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor. ( 29404984 )
2018
14
Simultaneous Glucagon and Vasoactive Intestinal Peptide Producing Pancreatic Neuroendocrine Tumors in a Patient With Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review. ( 29232343 )
2018
15
Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to<sup>177</sup>Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. ( 29331677 )
2018
16
Agenesis of dorsal pancreas associated with pancreatic neuroendocrine tumor: a case report and review of the literature. ( 29958547 )
2018
17
Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor. ( 29962731 )
2018
18
Soft Tissue Primary Neuroendocrine Tumor: A Case Report. ( 29967317 )
2018
19
Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. ( 29576279 )
2018
20
Long term recurrence in primary liver neuroendocrine tumor: Report of a single case and review of literature. ( 29896578 )
2018
21
Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. ( 29427030 )
2018
22
Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report. ( 29326972 )
2018
23
Neuroendocrine Tumor Diagnosis and Management: <sup>68</sup>Ga-DOTATATE PET/CT. ( 29975116 )
2018
24
Cystic pancreatic neuroendocrine tumor. Pancreatic endocrine or neuroendocrine tumor. Endoscopic ultrasonography. ( 29313698 )
2018
25
Letter to the editors regarding: genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: a 23-year experience at a single institution. ( 29338880 )
2018
26
Case Report of a Small Gastric Neuroendocrine Tumor in a Deep Layer of Submucosa With Diagnosis by Endoscopic Ultrasound-Guided Fine-Needle Aspiration and Treatment With Laparoscopic and Endoscopic Cooperative Surgery. ( 29371789 )
2018
27
A case of pancreatic neuroendocrine tumor with multiple cystic components of various sizes. ( 29270782 )
2018
28
Potentiation of <sup>177</sup>Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. ( 29872498 )
2018
29
Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. ( 29448303 )
2018
30
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. ( 29038234 )
2018
31
Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). ( 29325706 )
2018
32
Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. ( 29853889 )
2018
33
Underwater endoscopic mucosal resection: a new endoscopic method for resection of rectal neuroendocrine tumor grade 1 (carcinoid) a8oa8810a88mm in diameter. ( 29344571 )
2018
34
Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression. ( 29521944 )
2018
35
Two-stage resection of a bilateral pheochromocytoma and pancreatic neuroendocrine tumor in a patient with von Hippel-Lindau disease: A case report. ( 29501019 )
2018
36
Fine-needle aspiration of a pancreatic neuroendocrine tumor with prominent rhabdoid features. ( 29359517 )
2018
37
Gastric metastasis from pancreatic neuroendocrine tumor. ( 29634914 )
2018
38
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival with or without Liver Treatment. ( 29746336 )
2018
39
Neuroendocrine Tumor Therapy: <sup>177</sup>Lu-DOTATATE. ( 29949416 )
2018
40
Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. ( 29140113 )
2018
41
Differentiation between pancreatic metastases from clear cell renal cell carcinoma and pancreatic neuroendocrine tumor using double-echo chemical shift imaging. ( 29500651 )
2018
42
A Rare Case of Synchronous Papillary Microcarcinoma and Metastatic Neuroendocrine Tumor of Unknown Primary. ( 29430119 )
2018
43
Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection. ( 29563804 )
2018
44
Role of surgery in pancreatic neuroendocrine tumor. ( 29629318 )
2018
45
Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. ( 29107104 )
2018
46
Peripheral primitive neuroendocrine tumor of the chest wall-A case report with pathological correlation. ( 29904480 )
2018
47
Gastric neuroendocrine tumor arising from heterotopic pancreas. ( 29218566 )
2018
48
Pancreatic Collision Tumor of Ductal Adenocarcinoma and Neuroendocrine Tumor. ( 29850646 )
2018
49
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). ( 29330208 )
2018
50
Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. ( 29634977 )
2018

Variations for Neuroendocrine Tumor

ClinVar genetic disease variations for Neuroendocrine Tumor:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CDKN1B NM_004064.4(CDKN1B): c.127delCinsTAA (p.Arg43Terfs) indel Likely pathogenic rs797044481 GRCh37 Chromosome 12, 12870900: 12870900
2 CDKN1B NM_004064.4(CDKN1B): c.127delCinsTAA (p.Arg43Terfs) indel Likely pathogenic rs797044481 GRCh38 Chromosome 12, 12717966: 12717966
3 CDKN1B NM_004064.4(CDKN1B): c.279_280insT (p.Pro94Serfs) insertion Likely pathogenic rs797044482 GRCh38 Chromosome 12, 12718118: 12718119
4 CDKN1B NM_004064.4(CDKN1B): c.279_280insT (p.Pro94Serfs) insertion Likely pathogenic rs797044482 GRCh37 Chromosome 12, 12871052: 12871053
5 CDKN1B NM_004064.4(CDKN1B): c.334delA (p.Ser112Alafs) deletion Likely pathogenic rs797044483 GRCh38 Chromosome 12, 12718173: 12718173
6 CDKN1B NM_004064.4(CDKN1B): c.334delA (p.Ser112Alafs) deletion Likely pathogenic rs797044483 GRCh37 Chromosome 12, 12871107: 12871107

Cosmic variations for Neuroendocrine Tumor:

9
(show all 47)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.593T>C p.L198P 3:10149916-10149916 5
2 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.499C>T p.R167W 3:10149822-10149822 5
3 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 5
4 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 5
5 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 5
6 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 5
7 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.250G>A p.V84M 3:10142097-10142097 5
8 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 5
9 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 5
10 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 5
11 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 5
12 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 5
13 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 5
14 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 5
15 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.Q616fs*4 17:31225134-31225134 5
16 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.A548fs*13 17:31221932-31221932 5
17 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 5
18 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 5
19 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 5
20 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 5
21 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 5
22 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 5
23 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 5
24 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 5
25 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.4558C>T p.Q1520* 17:31260496-31260496 5
26 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 5
27 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.3721C>T p.R1241* 17:31235623-31235623 5
28 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.A776_Q803del 17:31227607-31227607 5
29 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.R69fs*7 17:31159009-31159009 5
30 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>T p.M118L 7:116699436-116699436 5
31 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.3029C>T p.T1010I 7:116771936-116771936 5
32 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.607T>A p.S203T 7:116699691-116699691 5
33 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.182A>G p.Q61R 11:533874-533874 5
34 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.181C>A p.Q61K 11:533875-533875 5
35 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.37G>C p.G13R 11:534286-534286 5
36 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,benign c.103G>T p.G35W 1:226064454-226064454 5
37 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1638C>A p.N546K 8:38417331-38417331 5
38 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1592C>T p.P531L 2:46380264-46380264 5
39 COSM6196778 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1104G>A p.M368I 2:46376608-46376608 5
40 COSM6196613 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1589C>A p.A530E 2:46380261-46380261 5
41 COSM6188649 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1595A>G p.Y532C 2:46380267-46380267 5
42 COSM17988 VHL adrenal gland,NS,pheochromocytoma,benign c.341-1G>T p.? 3:10146513-10146513 4
43 COSM144972 VHL adrenal gland,NS,pheochromocytoma,benign c.245G>T p.R82L 3:10142092-10142092 4
44 COSM144971 VHL adrenal gland,NS,pheochromocytoma,benign c.244C>G p.R82G 3:10142091-10142091 4
45 COSM3402726 NF1 adrenal gland,NS,pheochromocytoma,benign c.1307C>A p.S436* 17:31206286-31206286 4
46 COSM6476262 EPAS1 adrenal gland,NS,pheochromocytoma,benign c.1601C>T p.P534L 2:46380273-46380273 4
47 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,functioning c.133T>C p.S45P 3:41224645-41224645 3

Copy number variations for Neuroendocrine Tumor from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss C10orf57 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication C16orf45 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication C16orf63 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication KIAA0430 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain HER-2/neu Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication C9orf62 Neuroendocrine carcinoma

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 CALCA ENO2 NCAM1 NKX2-1 SYP
2 11.23 ASCL1 NCAM1 SYP
3 9.8 GAST GRP

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 CALCA CHGA CHGB GAST GRP NCAM1
2 secretory granule GO:0030141 9.13 CHGA CHGB SCG2

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.73 CALCA CHGB MEN1 SCG2
2 neuropeptide signaling pathway GO:0007218 9.67 CALCA GRP SSTR2
3 positive regulation of neural precursor cell proliferation GO:2000179 9.51 ASCL1 INSM1
4 positive regulation of cAMP metabolic process GO:0030816 9.48 CALCA CHGA
5 forebrain neuron differentiation GO:0021879 9.46 ASCL1 NKX2-1
6 sympathetic ganglion development GO:0061549 9.4 ASCL1 INSM1
7 type B pancreatic cell differentiation GO:0003309 9.37 INSM1 MEN1
8 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 9.32 CHGA GRP
9 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.26 ASCL1 NKX2-1
10 regulation of signaling receptor activity GO:0010469 9.17 CALCA CHGB GAST GRP NTS SCG2
11 noradrenergic neuron development GO:0003358 9.16 ASCL1 INSM1
12 adrenal chromaffin cell differentiation GO:0061104 8.96 ASCL1 INSM1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CALCA CHGB GAST SST

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....